 Paroxetine
"Paroxetine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotonin uptake inhibitor that is effective in the treatment of depression.
| Descriptor ID |
D017374
|
| MeSH Number(s) |
D03.383.621.600
|
| Concept/Terms |
Paroxetine Hydrochloride- Paroxetine Hydrochloride
- Paroxetine Hydrochloride Hemihydrate
- Hemihydrate, Paroxetine Hydrochloride
- Hydrochloride Hemihydrate, Paroxetine
- Paroxetine Hydrochloride, Hemihydrate
- Hemihydrate Paroxetine Hydrochloride
- Hydrochloride, Hemihydrate Paroxetine
|
Below are MeSH descriptors whose meaning is more general than "Paroxetine".
Below are MeSH descriptors whose meaning is more specific than "Paroxetine".
This graph shows the total number of publications written about "Paroxetine" by people in this website by year, and whether "Paroxetine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Paroxetine" by people in Profiles.
-
Carlson EL, Karuppagounder V, Pinamont WJ, Yoshioka NK, Ahmad A, Schott EM, Le Bleu HK, Zuscik MJ, Elbarbary RA, Kamal F. Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis. Sci Transl Med. 2021 02 10; 13(580).
-
Bos FM, Fried EI, Hollon SD, Bringmann LF, Dimidjian S, DeRubeis RJ, Bockting CLH. Cross-sectional networks of depressive symptoms before and after antidepressant medication treatment. Soc Psychiatry Psychiatr Epidemiol. 2018 Jun; 53(6):617-627.
-
Billups SJ, Delate T, Dugan D. Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations. Pharmacoepidemiol Drug Saf. 2009 Mar; 18(3):253-7.
-
Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007 Apr 26; 356(17):1711-22.
-
Chung KA, Carlson NE, Nutt JG. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology. 2005 May 24; 64(10):1797-8.
-
Schmaling KB, Dimidjian S, Katon W, Sullivan M. Response styles among patients with minor depression and dysthymia in primary care. J Abnorm Psychol. 2002 May; 111(2):350-6.
-
Lewis CF, DeQuardo JR, DuBose C, Tandon R. Acute angle-closure glaucoma and paroxetine. J Clin Psychiatry. 1997 Mar; 58(3):123-4.
-
Carpenter LL, McDougle CJ, Epperson CN, Price LH. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf. 1996 Aug; 15(2):116-34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|